What Is a Vascular Occlusion? An RN Explains the Signs and the Safety Plan

What is a vascular occlusion? It's a blocked blood vessel. After a cosmetic injection, it means dermal filler has cut off blood flow. Either the filler got inside a vessel and plugged it, or filler next to a vessel pressed on it from the outside. The tissue that vessel feeds stops getting enough blood. Without treatment, that tissue can be damaged, and in rare cases filler can affect the eye or the brain (ACE Group, J Clin Aesthet Dermatol, 2020; FDA).

It's rare, and it can be treated, especially with hyaluronic acid filler. The FDA still calls it the most concerning risk of dermal fillers. I'm Kat Chapman, BSN, RN, and I think every filler patient deserves a straight explanation before anyone picks up a syringe.

What is a vascular occlusion, in plain terms?

There are two ways filler can block blood flow.

From the inside. Filler is accidentally injected into a blood vessel. The FDA's safety communication explains that this can block the vessel and restrict blood supply, and that sometimes the filler travels to other parts of the body. That can cause skin damage and, rarely, vision loss, blindness, or stroke (FDA safety communication, May 2015, as reposted by the ASA). Of the proposed causes, this one has the best evidence behind it (ACE Group, 2020).

From the outside. Filler, or swelling from filler that draws in water, presses on a vessel. The evidence for this is thinner (ACE Group, 2020).

Where on the face it happens

It can happen anywhere filler goes. The FDA found it reported more often between the eyebrows, around the nose, on the forehead, and around the eyes (FDA safety communication).

For lip filler patients, this matters: in a study of 370 US dermatologists, the nasolabial folds and the lips were the sites most likely to have an occlusion, while average severity was highest between the brows (Alam et al., JAMA Dermatology, 2021). An expert consensus on vision loss calls the lips a high-incidence area for filler getting into a vessel, but only a moderate risk for vision problems. That group ranked facial areas by vision risk (Goodman et al., Aesthetic Surgery Journal, 2020):

This ranks vision risk only. A "low" area can still have an occlusion.

How rare is it?

In the dermatologist study, the risk never went above 1 occlusion per 5,000 syringes for any filler type. With needles it was about 1 in 6,410 syringes, with cannulas about 1 in 40,882, and 85% of occlusions left no lasting effects (Alam et al., 2021). The vision consensus estimates blindness at less than 1 in 100,000 syringes (Goodman et al., 2020).

Rare is not never, which is why the plan matters as much as the technique.

The signs, and why pain alone isn't enough

Here's how it tends to show up, per the ACE Group (ACE Group, 2020):

Numbing can hide pain. Before lip filler, my numbing cream goes on first, and most filler already has lidocaine in it, as my lip filler page says. The ACE Group warns that local anesthetic makes pain a less reliable warning sign, and that sudden or escalating pain during treatment or in the hours after needs an urgent look (ACE Group, 2020). Color matters as much as comfort.

A dark patch can look like a bruise. One difference the ACE Group notes: a bruise is blood that has leaked into the skin, so it doesn't blanch when pressed. They also say a suspected occlusion needs an in-person check, so please don't try to sort it out alone in the mirror (ACE Group, 2020).

Vision or stroke symptoms are an emergency. The vision consensus calls suspected vision loss "a true vascular emergency" and notes a stroke has been reported in 25% of patients with filler-related vision loss (Goodman et al., 2020).

How a trained injector lowers the risk

These are the habits the FDA and expert groups point to.

Knowing the anatomy. The FDA tells injectors to know the anatomy around each injection site, keeping in mind that blood vessels vary from person to person (FDA safety communication). That variation is why one review calls anatomy-based safety "only relative" (Goodman et al., Aesthetic Surgery Journal, 2022).

Going slow, with low pressure, in small amounts. The FDA's advice is to inject slowly with the least pressure necessary (FDA). The vision consensus recommends deposits under 0.1 mL with the needle kept moving, so very little filler goes in if the tip passes through a vessel (Goodman et al., 2020). The ACE Group adds that if more filler is needed, a second session 7 to 14 days later is safer than overfilling (ACE Group, 2020). That lines up with how I plan lip filler: build gradually, stop at natural, and add at the two-week follow-up if you want more.

Choosing a filler that can be dissolved. Hyaluronic acid (HA) filler can be broken down with an enzyme called hyaluronidase. The ACE Group suggests injectors, especially less experienced ones, consider using only reversible HA fillers for this reason (ACE Group, 2020). The FDA notes that permanent and non-HA fillers can be difficult or impossible to remove (FDA). For lips, I use reversible HA fillers.

Needle or cannula, chosen for the area. A cannula is a blunt-tipped tube. In the dermatologist study, cannula injections had 77.1% lower odds of occlusion than needle injections (Alam et al., 2021). But many experts don't consider cannulas safer in the nose, and thin cannulas (smaller than 25 gauge) can pierce vessels much like needles (Goodman et al., 2020). Another review notes cannulas are over-represented in reported blindness cases and concludes neither tool guarantees safety (Goodman et al., 2022).

Aspiration, and why it isn't a safety guarantee. Aspirating means pulling back on the plunger to check for blood before injecting. In lab studies it caught the vessel only 33% to 53% of the time. The vision consensus found no evidence it works as a safety measure and recommended against relying on it (Goodman et al., 2020; Goodman et al., 2022). The ACE Group still encourages it, but not as a stand-alone safety test (ACE Group, 2020). The experts disagree on whether to aspirate at all. They agree a "negative" result doesn't prove you're safe.

How a vascular occlusion is treated

Protocols differ in the details. The broad steps:

1. Stop injecting. The FDA tells injectors to stop immediately at any sign of a blocked vessel: blanching, a change in vision, signs of stroke, or unusual pain (FDA).
2. Check blood flow. The injector looks at skin color and capillary refill, meaning how fast color comes back after the skin is pressed. Refill that takes longer than three seconds suggests a problem (ACE Group, 2020).
3. Dissolve HA filler with hyaluronidase. Consensus protocols call for high doses over the whole area that's lost blood flow, repeated until color, refill, and pain improve. The ACE Group repeats it hourly (ACE Group, 2020); a later guideline suggests about every 15 to 20 minutes, treating "to effect" (Murray et al., 2021).
4. Get emergency care for vision symptoms. Suspected vision loss calls for transfer as early as possible to an emergency physician at an eye hospital or an experienced ophthalmologist, and hyaluronidase given at the clinic should not delay that transfer (Goodman et al., 2020).
5. Follow up in person until it's fully resolved, day by day at first if needed (ACE Group, 2020; Murray et al., 2021).

If you notice a warning sign after you've gone home and it's after hours, call me at (704) 584-9785. In an emergency, such as vision changes, trouble breathing, or severe pain with skin color change, call 911.

Why this matters when you choose an injector

The FDA tells injectors to have "an updated plan" for treating filler injected into a vessel (FDA). The vision consensus says every clinic must have hyaluronidase available for immediate use (Goodman et al., 2020). The ACE Group says patients should get an emergency number for after hours (ACE Group, 2020).

So before anyone injects filler into your face, ask:

1. Is hyaluronidase in this office right now, and is there enough on hand to treat an emergency?
2. Do you have a written plan for a vascular occlusion? Who does what, and where would I be sent?
3. Which filler are you using in my area, and can it be dissolved?
4. What's your training in facial anatomy and in filler complications? The FDA says to ask about training and experience (FDA).
5. Is a physician involved, and where is that physician during my appointment?
6. If something changes tonight, who do I call?

A good injector will answer all six without getting defensive. You can ask me every one of them at a consult. I keep hyaluronidase on hand, and I have a written emergency protocol for vascular occlusion.

As for number five: when you book with me, Dr. Stephen Giordano, DO (Dr. G) is in the room for every appointment. My site describes him as a board-certified physician with 23 years of practice and about 12 years in aesthetics. There's more on both of us on my About page and FAQ.

What I can't promise you

I can't promise zero risk. No one can. In the dermatologist study, 28.6% reported at least one occlusion over up to 10 years of practice, and the authors say their self-reported results don't carry over directly to nonphysician injectors like me (Alam et al., 2021).

Experience matters. That same study found injectors with more than five years of filler experience had 70.7% lower odds of an occlusion (Alam et al., 2021). I spent seven years as a Registered Nurse in ERs, on hospital floors, and on travel contracts across six states. I'm also new to aesthetic injecting, and I say so on my About page. You deserve to know both, and to know that Dr. G is in the room for every appointment.

Much of the treatment guidance is expert consensus, not large trials. The vision consensus notes "very limited evidence" for the in-clinic treatments it describes, and a short window to reverse blindness (Goodman et al., 2020).

Questions patients ask me about vascular occlusion

Can Botox cause a vascular occlusion?

Botox and other neurotoxins aren't fillers. The FDA's warnings about blocked blood vessels are about dermal filler, and so is the treatment guidance in this article (FDA). See whether Botox is safe for first-timers or my Botox page.

How soon after filler can a vascular occlusion show up?

Usually during the injection or within minutes. Color changes can take hours, and delayed cases have been published (ACE Group, 2020). The FDA's advice covers signs "during or shortly after the procedure" (FDA).

Can a vascular occlusion be reversed?

Often, yes, especially with HA filler, which hyaluronidase can dissolve (Murray et al., 2021). Vision loss is different. It's rare, it may be permanent, and time matters a great deal (Goodman et al., 2020).

Does this mean lip filler isn't safe?

It means lip filler is a medical procedure with a rare, serious risk and a known treatment plan. The FDA advises choosing a licensed, trained provider and treating filler as a medical procedure, not a cosmetic treatment (FDA). Whether it's right for you is a conversation for an in-person consult.

If you're weighing filler

Don't let anyone rush you. Start with my lip filler page, or look at cheek filler, jawline and chin filler, or how I plan facial balancing. Everything I offer is on the services page. When you're ready, book a free consult, or call or text me at (704) 584-9785.

This article is general education, not medical advice or a personal treatment plan. If you have symptoms after any injection, contact a healthcare provider right away. For vision changes or signs of a stroke, call 911 or go to the nearest emergency room.

Disclosure: I'm Kat Chapman, BSN, RN, and I perform the filler treatments mentioned in this article. Written by Kat Chapman, BSN, RN, October 2026.

Sources

• U.S. Food and Drug Administration. Dermal Fillers (Soft Tissue Fillers). https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/dermal-fillers-soft-tissue-fillers
• U.S. Food and Drug Administration. Unintentional Injection of Soft Tissue Filler into Blood Vessels in the Face: FDA Safety Communication, May 2015. The original FDA page is no longer live; full text as reposted by the American Society of Anesthesiologists: https://www.asahq.org/advocacy-and-asapac/fda-and-washington-alerts/fda-alerts/2015/05/unintentional-injection-of-soft-tissue-filler-into-blood-vessels-in-the-face
• King M, Walker L, Convery C, Davies E. Management of a Vascular Occlusion Associated with Cosmetic Injections. J Clin Aesthet Dermatol. 2020;13(1):E53-E58. https://pmc.ncbi.nlm.nih.gov/articles/PMC7028373/
• Murray G, Convery C, Walker L, Davies E. Guideline for the Safe Use of Hyaluronidase in Aesthetic Medicine, Including Modified High-dose Protocol. J Clin Aesthet Dermatol. 2021;14(8):E69-E75. https://pmc.ncbi.nlm.nih.gov/articles/PMC8570661/
• Goodman GJ, Magnusson MR, Callan P, et al. A Consensus on Minimizing the Risk of Hyaluronic Acid Embolic Visual Loss and Suggestions for Immediate Bedside Management. Aesthet Surg J. 2020;40(9):1009-1021. https://pmc.ncbi.nlm.nih.gov/articles/PMC7427155/
• Goodman GJ, Magnusson MR, Callan P, et al. Aspiration Before Tissue Filler: An Exercise in Futility and Unsafe Practice. Aesthet Surg J. 2022;42(1):89-101. https://pmc.ncbi.nlm.nih.gov/articles/PMC8670299/
• Alam M, Kakar R, Dover JS, et al. Rates of Vascular Occlusion Associated With Using Needles vs Cannulas for Filler Injection. JAMA Dermatol. 2021;157(2):174-180. https://pmc.ncbi.nlm.nih.gov/articles/PMC7774041/